The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), Johnson & Johnson (Gold), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | The promise of MRD-adapted treatment strategies in CLL
Talha Munir, MBBS, MRCP, FRCPath, PhD, Leeds Teaching Hospitals NHS Trust, Leeds, UK, discusses the evolving role of measurable residual disease (MRD)-guided treatment in chronic lymphocytic leukemia (CLL). He outlines the potential advantages of tailoring treatment duration based on individual patient response, highlights the patients most likely to benefit from fixed-duration approaches, and reviews the evidence needed for MRD-adapted therapy to become part of routine clinical practice. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
